Latest News

BEDFORD, Mass. — Ocular Therapeutix Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Food and Drug Administration (FDA) has agreed to a Special Protocol Assessment (SPA) Agreement Modification for the Company’s pivotal...
The Ogun State government has purchased a large quantity of drugs to fight schistosomiasis – a water borne disease caused by worms – which is prevalent in parts of the state, the state commissioner for health, Abiodun Oduwole has said. Mrs. Oduwole said this on Tuesday, during a meeting with...
NEW YORK, NY – Olatec Therapeutics, Inc., a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson’s granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow or stop the progression of Parkinson’s disease. Parkinson’s is a...
The combination of cancer therapy lenalidomide plus the steroid dexamethasone (together called Rd) is considered standard treatment for elderly patients with multiple myeloma. However, prolonged steroid use can be harmful for some older adults. A new study published in Blood found that switching select older patients to a lower dose...
BOONE, N.C. – A biological anthropologist from Appalachian State University working with an undergraduate student from Appalachian, an evolutionary biologist from UNC Greensboro, and a team of archaeologists from Deccan College (Pune, India) recently reported analysis of a 4000-year-old skeleton from India bearing evidence of leprosy. This skeleton represents both...
WHITE PLAINS, N.Y. – Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the appointment of William Erhardt, M.D., Chief Medical Officer of Oligomerix, to its Board of Directors. “As Chief Medical Officer, Bill has provided...